Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remicade vs Methotrexate in Moderate to Severe Psoriasis
NCT00251641Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2005
- Primary completion
- Jun 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of infliximab in plaque psoriasis (2 arms), sponsored by Merck & Co. Primary endpoint: Psoriasis Area and Severity Index 75 at 16 weeks. Started Sep 2005; status: completed.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00251641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251641.